Showing results (1-10 of 116) with videos related to
Sort By:
Pageof 12
Bulletin of the NYU Hospital for Joint Diseases|June 22, 2007
Predicting response to TNF antagonists in rheumatoid arthritis: the promise of pharmacogenetics research using clinical registriesJeffrey D Greenberg, Harry OstrerBulletin of the NYU Hospital for Joint Diseases|October 10, 2007
TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registriesAdeel Nasir, Jeffrey D GreenbergNature Clinical Practice. Rheumatology|February 21, 2008
Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction?Steven B Abramson, Jeffrey D GreenbergNature Reviews. Rheumatology|May 5, 2009
Assessing infection risk with biologic agents in RA: methodological challengesMark C Fisher, Jeffrey D GreenbergNature Reviews. Rheumatology|October 3, 2009
Dendritic cells as targets for therapy in rheumatoid arthritisShaukat Khan, Jeffrey D Greenberg, Nina BhardwajNature Reviews. Rheumatology|November 16, 2011
Cardiovascular safety of biologic therapies for the treatment of RAJeffrey D Greenberg, Victoria Furer, Michael E FarkouhCurrent Opinion in Rheumatology|March 20, 2008
The role of drug and disease registries in rheumatic disease epidemiologyJoel M Kremer, Allan Gibofsky, Jeffrey D GreenbergThe Journal of Rheumatology|July 3, 2010
A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological researchMary J Bentley, Jeffrey D Greenberg, George W ReedExpert Review of Clinical Immunology|May 19, 2010
Lumiracoxib, a highly selective COX-2 inhibitorRaban V Jeger, Jeffrey D Greenberg, Krishnan Ramanathan, et al.Arthritis Care & Research|February 7, 2018
Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative DataJeffrey R Curtis, Fenglong Xie, Lang Chen, et al.Pageof 12